We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Strategies & Market TrendsSpeculating in Takeover Targets

Previous 10 Next 10 
To: richardred who wrote (3421)2/11/2014 1:27:22 PM
From: richardred
   of 6568
RE-CPIX IMO FWIW Little CPIX also has a little kicker. Caldolor® (ibuprofen) Injection, the first injectable treatment for pain and fever approved in the United States. The SA guy doesn't like this as much now RE:Hepatoren drug candidate
The Success Of Intercept Pharmaceuticals Is A Negative For Cumberland Pharmaceuticals.

No shot in the arm today, but with 3 1/2 in cash and total debt covered 10X current cash. Just maybe there's a chance for the early bird to get the worm.

Mallinckrodt acquires San Diego pharma firm Cadence for $1.3 billion

Cadence Pharmaceuticals makes Ofirmev, an injectable version of the drug acetaminophen, the active ingredient in Tylenol. (Rajesh Kumar Singh / Associated Press)

By Stuart Pfeifer

February 11, 2014, 9:02 a.m.

Ireland pharmaceutical company Mallinckrodt has agreed to acquire San Diego company Cadence Pharmaceuticals for about $1.3 billion in an effort to boost its specialty drugs portfolio.

Cadence, which commercializes drugs that are used in hospitals, is best known for Ofirmev, an injectable version of the drug acetaminophen, the active ingredient in Tylenol. Launched in January 2011, Ofirmev has been used to treat an estimated 6 million to 7 million patients.

Photos: Top 10 Southern California companies

“The acquisition of Cadence Pharmaceuticals is consistent with our goal of becoming a leading global specialty pharmaceuticals company,” said Mark Trudeau, chief executive of Mallinckrodt. "Ofirmev’s growth is driven by an expanding base of physicians who are prescribing the product for an increasing number of surgical patients, and we believe the product will be an outstanding addition to the brands component of Mallinckrodt’s specialty pharmaceutical segment.

"We have been impressed with the strong relationships that Cadence’s commercial organizations have established with customers in the hospital channel and are excited by the opportunity to build on these relationships to expand our platform in this area."

Cadence shares surged $2.91, or 26%, to $13.98 in morning trading.

“We are very proud of what our employees have accomplished, and in particular the very strong growth we have achieved with Ofirmev,” said Ted Schroeder, chief executive of Cadence Pharmaceuticals. “The relationships we’ve established with our customers and the benefits the drug has provided to millions of patients across the U.S. have contributed to the strong year-on-year growth we’ve seen for the product since launch.

"We believe Mallinckrodt is a natural fit to provide the resources and expertise that can expand patient access for Ofirmev. Additionally, this transaction will provide Cadence shareholders with a strong return on their investment.”

Mallinckrodt agreed to pay $14 per share for the company, a 27% premium to Cadence's Monday closing price of $11.07. The boards of both companies have approved the deal.

The acquisition, expected to close in March, will "significantly" boost Mallinckrodt's earnings per share, the company said in a news release.

Mallinckrodt shares were up $5.71, or 10%, at $65.02 Tuesday morning. The company reported net sales of $2.2 billion in its 2013 fiscal year, up from $2.1 billion the prior year. It has traded on the New York Stock Exchange since July, when it separated from former parent company Covidien.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)

To: richardred who wrote (3234)2/12/2014 11:10:43 AM
From: richardred
   of 6568
Grupo Bimbo to Buy Canada Bread for $1.7 Billion By WILLIAM ALDEN

Tony Cenicola/The New York Times Grupo Bimbo already has a number of well-known bread brands, including Thomas’ English muffins.

Grupo Bimbo, the Mexican baking giant, is expanding across North American for its latest bread deal.

The company has agreed to buy Canada Bread, a Toronto-based baking company that is 90 percent owned by Maple Leaf Foods, for $1.83 billion Canadian dollars, or $1.67 billion, according to an announcement on Wednesday.

Including a recent dividend paid by Canada Bread, the offer of 72 Canadian dollars a share represents a 31 percent premium over the company’s closing price on Oct. 18, the day before Maple Leaf said it was exploring strategic options for the business. It is also a 34 percent premium over the 20-day volume-weighted average stock price ending Oct. 18.

Maple Leaf has agreed to vote its shares in favor of the deal, Canada Bread said in its announcement. Investors appear to be expecting the deal to go through, sending shares of Canada Bread, which is listed on the Toronto Stock Exchange, up 7 percent on Wednesday to 72.05 Canadian dollars.

Grupo Bimbo already has a number of well-known bread brands in its portfolio, including parts of Entenmann’s, Thomas’ English muffins and Sara Lee bakery. In 2012, it was seen as a potential suitor for Hostess Brands.

Its deal for Canada Bread, subject to regulatory approval, is expected to close in the second quarter of this year. Under the deal’s terms, Canada Bread can pay quarterly dividends of up to 75 Canadian cents a share until the transaction closes.

“This is an excellent outcome for our bakery businesses and shareholders,” Richard Lan, the president and chief executive of Canada Bread, said in a statement. “Becoming part of Grupo Bimbo, the world’s leading bakery company, and benefiting from its focus, expertise and resources, will create new opportunities for our people, customers and business partners.”

A special committee of independent directors of Canada Bread received legal and financial advice, as well as a fairness opinion, from CIBC World Markets.

Share RecommendKeepReplyMark as Last Read

To: richardred who wrote (3536)2/12/2014 11:18:30 AM
From: richardred
   of 6568
Imerys to Buy U.S. Materials Firm For $1.6 Billion The French specialty materials maker said it expected the acquisition of Amcol International to “generate significant commercial and operational synergies.

Share RecommendKeepReplyMark as Last Read

To: richardred who wrote (3571)2/13/2014 10:32:41 AM
From: richardred
1 Recommendation   of 6568
IMO and miles to go before they can complete.

Comcast’s Deal for Time Warner Is Big Win for Advisers

Comcast’s $45 billion takeover of Time Warner Cable isn’t just a victory for the cable giant. It’s also an unexpected win for the company’s advisers.

For months, it had seemed as though the bevy of banks and law firms working for Charter Communications, the unwanted suitor for Time Warner Cable, were in a position to score a big payday. Its only real rival, Comcast, was in talks to buy a handful of markets from Charter should it have succeeded.

Obviously, things took a different turn in recent days.

Comcast’s financial advisers stand to make $51 million to $68 million in fees, according to estimates from Freeman & Company. Time Warner Cable’s banks could earn $57 million to $75 million.

Comcast was advised by:

The deal is particularly big for Mr. Taubman, who already has one major transaction under his belt since striking out on his own: Verizon Communications’ $130 billion purchase of the 45 percent stake in its wireless business owned by Vodafone. He has long counted Comcast as a client, having spearheaded its deal for NBC Universal.

Share RecommendKeepReplyMark as Last Read

From: Glenn Petersen2/14/2014 5:25:26 PM
1 Recommendation   of 6568
Jos. A. Bank Takes a Page From a Long Ago Deal

New York Times
February 14, 2014, 4:55 pm

In purchasing Eddie Bauer, Jos. A. Bank Clothiers has cleverly structured its deal to try and avoid criticism that its pursuit of Eddie Bauer shuts down Men’s Wearhouse’s own bid for the men’s clothing company. It’s a deft maneuver, based on both Delaware law and a bit of ancient history.

Back in 1989, Paramount made a hostile offer for the company then known as Time Inc. Time had agreed to a business combination with Warner Communications. But Paramount’s offer appeared to create more value. In the face of having to try to convince its own shareholders to reject the Paramount deal and go ahead with the Warner merger, Time’s board opted to steamroll its own shareholders. Time restructured the Warner deal so it would be a straight out cash acquisition. The deal would effectively be a poison pill, since it made Time too big and too leveraged to be acquired by Paramount. The fact that many Time shareholders favored the Paramount bid was beside the point.

Paramount sued, but the Delaware Supreme Court sided with Time. The court held that so long as Time’s board had not agreed to a change of control, the acquisition could not be challenged. Time had adequately documented its strategic reasons for doing the deal, so it was free to acquire Warner even though it had effectively blocked the more valuable Paramount deal.

The decision upheld the principle that company boards could make acquisitions, even ones that blocked competing offers, with relative impunity. Shareholders could do nothing to stop it. Other countries, including the United Kingdom, require a significant vote on an acquisition to prevent these maneuvers, but most states in the United States do not.

Jos. A. Bank could thus have simply acquired Eddie Bauer without shareholder approval.

But if Jos. A Bank had simply done this, it would have been criticized for appearing to try to end the Men’s Wearhouse bid — a combination that seemed to make sense to both companies, which in the space of a year, have offered to acquire each other.

Instead, Jos. A Bank voluntarily put in its acquisition agreement a way out if Men’s Wearhouse comes back.

The Eddie Bauer acquisition agreement permits Jos. A. Bank to terminate the deal if a superior proposal is made for Jos. A Bank. A superior proposal is defined in the agreement as a proposal that provides for a full acquisition of Jos. A. Bank and that the Jos. A Bank board determines “would reasonably be expected to create greater value” than the Eddie Bauer acquisition and the plan to buy back up to $300 million of its own stock that the company also announced on Friday.

If Jos. A. Bank does receive a superior proposal, its board can terminate the Eddie Bauer acquisition by paying $48 million to Eddie Bauer’s owner, Golden Gate Capital. This corresponds to 3 percent of the value of Jos. A. Bank, based on the $57.50 offer price by Men’s Wearhouse. This is within the range of termination fees that targets typically pay if a subsequent bidder comes along.

Because this deal is, in part, structured like a private equity deal, if Jos. A. Bank’s financing falls through, Eddie Bauer can terminate the acquisition agreement and Jos. A Bank will be required to pay $55 million to Eddie Bauer’s owners. Otherwise, Jos. A. Bank can be forced to complete the deal.

The right to an exit that Jos. A. Bank negotiated is a clever maneuver. It allows Jos. A. Bank to say publicly to its shareholders: Look, we are acting in your best interests, and, in fact, we actually negotiated an out to take a better deal if it should come along.

But at the same time, the provision leaves the decision solely with Jos. A. Bank’s board. Given that antitrust regulators are still reviewing the Men’s Wearhouse’s bid, Jos. A. Bank’s board has a wide open hole to just say no to the Men’s Wearhouse bid. The more immediate value, the board could argue, is in the Eddie Bauer transaction. Men’s Wearhouse would have to come back with quite a bid to overcome this presumption, something it no doubt knows and many in the media speculated it was unlikely to do.

So Jos. A Bank cleverly gets around the heavy-handedness of appeared to unilaterally end the Men’s Wearhouse bid though a maneuver similar to Time’s while also getting its escape. Nice. It all means that what many investors who thought a combination of Men’s Wearhouse and Jos. A. Bank was a done deal are now left to see it as a dim alternative.

Steven M. Davidoff, a professor at the Michael E. Moritz College of Law at Ohio State University, is the author of “ Gods at War: Shotgun Takeovers, Government by Deal and the Private Equity Implosion.” E-mail: | Twitter: @StevenDavidoff

Share RecommendKeepReplyMark as Last ReadRead Replies (2)

To: Glenn Petersen who wrote (3635)2/15/2014 12:19:18 PM
From: richardred
1 Recommendation   of 6568
Glen: Very interesting precedent. Thanks for jogging my memory. Most of use who dealt with hostile takeover battles over the years have heard of the famed Pac-Man defense. Which I though was a remote possibility, but it looks like Bank took the Fat Man route. Maybe the Dealbook author wasn't aware of FAT MAN Strategy? The piece just sounds to *blasé without it. Or maybe my tie in reference is a little to *PASSÉ. :+ )

Definition of 'Fat Man Strategy '

A takeover defense tactic that involves the acquisition of a business or assets by a target company. The strategy is based on the premise that the bulked-up company - the "fat man" - would have reduced appeal to a hostile bidder, especially if the acquisition increases the acquirer's debt load or decreases available cash.

P.S. related piece
Could Jos. A. Bank's Eddie Bauer buy boost Sears?For years now, an investment in Sears Holdings Inc. ( SHLD) has mostly hinged on how much the company’s various bits and pieces were worth to someone else on the open market.

The next bit of Sears merchandise expected to hit the market is Lands' End, the venerable direct seller of clothing and outdoor gear the company acquired for $1.9 billion in 2002. Sears is now preparing to spin Lands' End off to shareholders.

The news on Friday that men’s apparel retailer Jos. A Bank Clothiers Inc. ( JOSB) agreed to acquire Eddie Bauer from its private-equity owners, Golden Gate Capital, for $825 million offers a decent benchmark for gauging what Lands' End might be worth once it's set free.

Both Lands' End and Eddie Bauer are long-established American brands that began selling a similar mix of outdoorsy, utilitarian clothes and gear and have since broadened the fashion mix. The bottom line: Based on a rough comparison, Lands' End appears to be worth at least 10% and perhaps more than 20% of Sears’s current $4.5 billion stock-market value.

Jos. A. Bank is paying for Eddie Bauer in a mix of cash and stock, as well as a possible earn-out payment based on future performance. Jos. A. Bank — which has traded hostile takeover bids with Men’s Wearhouse Inc. ( MW) in recent months — said the purchase price essentially equals Eddie Bauer’s 2013 revenue and amounts to 9.5-times its adjusted earnings before interest, taxes, depreciation and amortization.

A generous valuation

This looks to be a somewhat generous valuation of adjusted EBITDA. In 2010 J. Crew was taken private at a multiple of about 9-times the prior year’s Ebitda (a proxy for cash flow). J. Crew is arguably a stronger brand and appeared to have had higher profit margins than Bauer.

Sears has filed financial information for Lands' End through October of 2013, but not yet for the full fiscal year. The company over the past couple of years has collected about $1.5 billion in annual revenue and was on target in 2013 for around $100 million in adjusted EBITDA. So at the revenue multiple Jos. A. Bank is paying for Eddie Bauer, Lands' End would be worth some $1.5 billion and, at Bauer’s cash-flow valuation, just under $1 billion. Lands' End's business is more heavily skewed toward direct sales (Internet and catalogue) than is Eddie Bauer's. This should in theory add to Lands' End's value, though its profit margins don't appear to be appreciably higher.

There are several caveats. First is that these reflect “enterprise value,” which adds equity value plus any net debt held by the company. Based on Sears’ spinoff filing, Lands' End intends to take on a $500 million term loan and use the cash to pay a dividend to Sears prior to the spinoff. (Such maneuvers are relatively common in spinoffs.)

So if Lands' End carries that $500 million in debt, and enterprise value (based on Eddie Bauer’s deal price) is to be in the range of $1 billion to $1.5 billion, it means the equity value of Lands' End to stock investors would be $500 million to $1 billion.

Another complication is that Jos. A. Bank seems to have moved to buy Eddie Bauer with some extenuating motives that could have inflated the price it paid. For one, the company warned of a badly eroding outlook for the core Bank business at the same time it announced the deal. Second, it’s using a complicated structure that gives Golden Gate Capital a 16.6% stake in Jos. A. Bank and provides for a steep $50 million termination fee if the deal is canceled.

This appears intended as a sort of “poison pill” defense, to make an acquisition of Jos. A. Bank vastly more expensive and difficult for Men’s Wearhouse. Breakout's Jeff Macke riffs here about Bank management's desperate hunt to increase shareholder value with a struggling core business. Bank management’s willingness to pay such a full price for Eddie Bauer could reflect its own unique objectives more than the intrinsic value of the Eddie Bauer business – which Golden Gate acquired out of bankruptcy in 2009 for less than $300 million.

Chains in decline

At the core of Sears Holdings, of course, is a pair of broad-line retail chains in decline, a combined total of 2,000 Kmart and Sears stores suffering depressed customer traffic and sliding sales, and operating in the red.

Yet under chairman and principal shareholder Edward Lampert, the company has been aggressively hiving off subsidiaries and real estate. He has spun off Sears Canada Ltd. ( SEARF) and Sears Hometown and Outlet Stores Inc. ( SHOS). He's also sold a lease on Sears's Honolulu store for some $200 million and created an internal real-estate development division to actively market Sears and Kmart store locations for use as data centers and other non-retail purposes.

*P.S. RE: blasé/PASSÉ Me and my best friend from chess club used the French words all the time back in high school. This when he first quipped the words while playing against him. It stuck in appropriate times after that.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)

From: richardred2/18/2014 9:05:16 AM
   of 6568
Big deal toady FRX Forest Labs

Drug Makers in $25 Billion Deal By DAVID GELLES

Dario Cantatore/NYSE Euronext Paul Bisaro, the chairman and chief executive of Actavis, will lead the combined company.
    e-mail facebook twitter save more

Updated, 8:30 a.m. |

Actavis said on Tuesday that it had reached an agreement to acquire Forest Laboratories for $25 billion in cash and stock in a deal that would create a huge pharmaceuticals company with heavy exposure to both branded and generic drugs.

The deal marks the biggest deal yet for one of the pharmaceutical industry’s most aggressive buyers, and a major win for Carl C. Icahn, who had been agitating for change at Forest.

Actavis, based in Dublin but operating from Parsippany, N..J., has been an aggressive acquirer of other drug companies. The latest acquisition — its largest by far — will be its seventh since January 2013, according to Standard & Poor’s Capital IQ. The combined revenues of the two fast-growing specialty pharmaceutical companies are expected to be more than $15 billion in 2015, the companies said.

Under the terms of the deal, Forest shareholders will receive $26.04 in cash and 0.3306 of a share of Actaivs or $89.48. That represents a premium of 25 percent from Forest’s closing stock price on Friday. The stock portion of the payment will be tax-free for Actavis.

Related Links

Shares of Forest were up more than 30 percent in premarket trading, while Actavis shares were up 12 percent as investors cheered news of the deal.

Actavis has historically been focused on generic drugs, but in recent years has expanded into selling more branded pharmaceuticals. Forest’s best known drugs are Lexapro and Namenda.

“Today we create a new kind of specialty pharmaceutical company, and one that’s really grounded in something different — a generic DNA,” Paul Bisaro, the chairman and chief executive of Actavis, said in a conference call. “We will have a balanced portfolio of branded and generic offerings.”

This is the first major deal Actavis has announced since it completed its takeover of Warner Chilcott last year for about $5 billion. That deal expanded Actavis’ presence in specialty pharmaceuticals, and also allowed it to complete a so-called tax inversion, relocating its headquarters to Ireland and escaping the U.S. tax regime.

One big advantage of tax inversions, besides a lower statutory tax rate, is that deals can become more affordable. Once inverted, companies can more easily use overseas cash to pay for a deal, and the earnings from any acquired company are also taxed at the company’s new, lower rate.

In this case, Forest’s earnings, which had been getting taxed at a higher U.S. rate, will eventually be taxed at the lower Irish rate currently paid by Actavis, which executives estimated to be 16 percent. Tax savings will amount to at least $100 million, the company’s said.

Mr. Bisaro, who will lead the combined company, said that the deal would result in at least $1 billion in pre-tax and tax savings in the first years of the combination.

The deal is a huge win Mr. Icahn, who led an unsuccessful proxy fight at Forest in 2011 before gaining a board seat and has advocated for changes at the drug maker. He owns more than 11 percent of Forest, according to Dec. 31 filings.

“Great result for ALL $FRX (Forest Labs) shareholders,” Mr. Icahn wrote on Twitter. “Proves again that activism works.”

And though Actavis has been known to grow through acquisition, the enlarged company is already pledging to aggressively develop new drugs. The combined company will spend $1 billion in research and development in its first year, executives said, and already has many products in Phase 3 and 2 research.

Actavis said it planned to release its quarterly results as planned on Thursday, but would not hold a conference call to discuss results.

The companies anticipate closing the deal during the middle of next year. The companies does not expect any significant divestitures.

“When you look at the overview of Forest strategy, it will remain alive and well,” said Forest’s chief executive Paul Bisaro on a conference call. “We believe the optionally for future grown is incredible strong.”

Though Actavis has bridge loan commitments from Bank of America Merrill Lynch and Mizuho Bank, Mr. Bisaro said “we are not over levering ourselves” to get this done.

Greenhill & Company and the law firm Latham & Watkins advised Actavis. JPMorgan Chase is serving as financial adviser to Forest, and Wachtell, Lipton, Rosen & Katz is serving as its legal adviser.

Share RecommendKeepReplyMark as Last Read

From: richardred2/18/2014 11:00:40 AM
   of 6568
New buy today- Re-entry of LNCE-Synder's/Lance

Share RecommendKeepReplyMark as Last ReadRead Replies (3)

To: richardred who wrote (3624)2/20/2014 1:51:25 PM
From: richardred
   of 6568
RE- UNTD Due to the dividend suspension. I'm guessing the big former dividend holders covered some their short position today. I think favorable subscriber growth is what the excitement might be about today? Big swing either way.

Share RecommendKeepReplyMark as Last Read

To: richardred who wrote (3629)2/21/2014 12:14:53 AM
From: richardred
   of 6568
Facebook answers back at Google.

Wall Street sees sense in Facebook's $19 billion WhatsApp buy

(Reuters) - Facebook Inc's purchase of fast-growing messaging startup WhatsApp for an eye-popping $19 billion largely won approval from analysts, who said the deal made strategic sense as it will solidify the social network's position as a leader in mobile.

Facebook shares closed up 2.3 percent at $69.63 after falling as much as 3 percent in early trading as investors got over the initial sticker shock of the deal value.

At least two brokerages downgraded their recommendations on Facebook to "hold" but the overwhelming majority of analysts remain positive on the stock.

Facebook is paying more than double its annual revenue for a chat program that has little revenue. The purchase price is slightly more than the market value of Sony Corp.

But analysts noted that WhatsApp has over 450 million users and boasts a higher level of engagement than Facebook.

"Facebook is the leading global social-sharing utility. Now, it has a significant opportunity to be the leading global communications utility," RBC Capital Markets said in a note.

WhatsApp is much stronger than Facebook Messenger in Europe, Latin America, Africa and Australia and has attracted users at a time when it appears that young people are turning away from Facebook.

Analysts said the price tag for WhatsApp, founded in 2009 by former Yahoo Inc employees Jan Koum and Brian Acton, seemed reasonable from the point of view of value per user.

Facebook is paying $42 per user, compared with a market value per user of $170 for Facebook and $212 for Twitter, Deutsche Bank's Ross Sandler said.

WhatsApp's user base is less than half that of Facebook's 1.2 billion but the chat program's users are more active. On any given day, 70 percent of WhatsApp users are active, compared with 62 percent for Facebook. WhatsApp's users are expected to reach 1 billion by 2015, according to many analysts.

"Looking past the sticker shock of $19 billion ... We view (the deal) as an offensive move to gain additional share of the consumer's time spent," Credit Suisse analysts said, noting that Facebook was paying about 11 percent of its market value to gain a 30 percent rise in engagement.


Of the 44 analysts who cover Facebook, 37 have a "buy" or a "strong buy" rating on the stock, according to Thomson Reuters data. None has a "sell" rating.

Analysts have commended Facebook's ability to make money from its mobile app. Now they will want to see how it will earn money from the chat app's huge number of users.

"While we don't expect messaging to be a meaningful near-term or even long-term revenue driver, the real value could be the evolution of the platform to incorporate new functionality such as payments, app distribution, social features ...," Macquarie Equities Research analyst Ben Schachter said.

Facebook has fallen behind in mobile phone messaging apps in emerging markets, where many are accessing the Internet on fast-growing 3G mobile networks for the first time on smartphones.

Asian rivals such as Tencent Holdings Ltd's WeChat, Naver Corp's Line and Rakuten Inc's Viber are well ahead of Facebook messenger across much of Asia.

Facebook has been buying apps with large numbers of young users as part of Chief Executive Officer Mark Zuckerberg's strategy of helping users share any kind of content with anyone.

The company's $1 billion deal to buy photo-sharing application Instagram in 2012 and its recent $3 billion failed overture to buy SnapChat - used by teenagers to send texts and photos that disappear after a few seconds - followed unsuccessful attempts to develop rival apps.

"Large-scale networks like WhatsApp are rare and provide (a) significant monetization opportunity (i.e. YouTube) justifying valuation over time," SunTrust Robinson Humphrey's Robert Peck said in a note.

Analysts estimate WhatsApp users share 19 billion messages, 600 million photos, 200 million voice messages, and 100 million video messages per day.

Still, some analysts said Facebook was paying a high price to keep WhatsApp from being snapped up by a rival such as Google Inc.

"Facebook shares would have been pressured by more than single-digit percentages in after-market trading if Google had purchased WhatsApp instead," Stifel analyst Jordan Rohan said in a note.

Pivotal Research's Brian Wieser, who downgraded his rating on Facebook shares to "hold" from "buy," said he expects Facebook shares to face pressure in the near-term as investors come to terms with the risk of future acquisitions.

(Reporting by Soham Chatterjee and Saqib Iqbal Ahmed in Bangalore; Editing by Saumyadeb Chakrabarty and Lisa Shumaker)

Share RecommendKeepReplyMark as Last Read
Previous 10 Next 10